Program
Amphotericin B
Also written as “Amphotericin B Liposome for Injection (strength: 50 mg, Sichuan Huiyu Pharmaceutical Co., Ltd.)”, “Amphotericin B Liposome for Injection (trade name: Ambisome®, strength: 50 mg, MAH: Gilead Sciences)” and “Amphotericin B Liposome”.
Its studies are mostly in Meningitis, Cryptococcal · Invasive Fungal Infections · Leishmaniasis, Visceral · Aspergillosis · Candidiasis, led by 9 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 60 open or running | phase 3since Nov 2, 1999 | Nov 2, 1999 | none ahead |
| Alkermes | 10 open or running | phase 1since Nov 2, 1999 | Nov 2, 1999 | none ahead |
| Aurobindo Pharma | 10 open or running | phase 1since Aug 6, 2018 | Aug 6, 2018 | none ahead |
| Bristol-Myers Squibb | 10 open or running | no phasesince Nov 2, 1999 | Nov 2, 1999 | none ahead |
| Johnson & Johnson | 10 open or running | phase 3since Nov 2, 1999 | Nov 2, 1999 | none ahead |
| Liposome | 10 open or running | no phasesince Nov 2, 1999 | Nov 2, 1999 | none ahead |
| Matinas BioPharma Nanotechnologies | 10 open or running | phase 2since Nov 16, 2015 | Nov 16, 2015 | none ahead |
| Merck | 10 open or running | phase 2since Feb 5, 2004 | Feb 5, 2004 | none ahead |
| Sichuan Huiyu Pharmaceutical | 10 open or running | no phasesince Apr 30, 2025 | Apr 30, 2025 | none ahead |
Also a collaborator on its studies: axis-clinicals-limited.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 2, 1999First study: phase 1 study in Meningitis, CryptococcalNew to AlkermesAlkermes · NCT00002316 · United States
- Nov 2, 1999First studies: 4 no phase studies in Meningitis, CryptococcalNew to PfizerPfizer · NCT00002305, NCT00002075, NCT00002074 and 1 more
- Nov 2, 19992 phase 3 studiesPfizer · NCT00002277, NCT00001017
- Nov 2, 1999First study: phase 3 study in HIV InfectionsNew to Johnson & JohnsonJohnson & Johnson · NCT00002159 · 60 enrolled · United States
- Nov 2, 1999First study: no phase study in CandidiasisNew to Bristol-Myers SquibbBristol-Myers Squibb · NCT00002041 · United States
- Nov 2, 1999First study: no phase study in Meningitis, CryptococcalNew to LiposomeLiposome · NCT00002019 · United States
- Feb 5, 2004Merck's first study: phase 2 study in AspergillosisNew to MerckMerck · NCT00076869 · 55 enrolled
- Nov 16, 2015Matinas BioPharma Nanotechnologies's first study: phase 2 study in Candidiasis, Chronic MucocutaneousNew to Matinas BioPharma NanotechnologiesMatinas BioPharma Nanotechnologies · NCT02629419 · 4 enrolled · United States
- Aug 6, 2018Aurobindo Pharma's first study: phase 1 study in Leishmaniasis, VisceralNew to Aurobindo PharmaAurobindo Pharma · NCT03636659 · 140 enrolled · Bangladesh, India
- Apr 30, 2025Sichuan Huiyu Pharmaceutical's first study: no phase study in Invasive Fungal InfectionsNew to Sichuan Huiyu PharmaceuticalSichuan Huiyu Pharmaceutical · NCT06977490 · 42 enrolled · China
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Ergosterol sequestering agent”ChEMBL 37, by rule
Studies
All 14 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06977490Invasive Fungal Infections · China | – | Completed | Sichuan Huiyu Pharmaceutical | Oct 7, 2025 | 42 |
| NCT03636659Leishmaniasis, Visceral · Bangladesh, India | 1 | Completed | Aurobindo Pharma | Apr 5, 2019 | 140 |
| NCT02629419Candidiasis, Chronic Mucocutaneous · United States | 2 | Completed | Matinas BioPharma Nanotechnologies | Nov 9, 2021 | 4 |
| NCT00076869Aspergillosis | 2 | Completed | Merck | Sep 2004 | 55 |
| NCT00002316Meningitis, Cryptococcal · United States | 1 | Completed | Alkermes | ||
| NCT00002305Meningitis, Cryptococcal · United States, Canada | – | Completed | Pfizer | ||
| NCT00002277Mycoses · United States | 3 | Completed | Pfizer | ||
| NCT00002159HIV Infections · United States | 3 | Completed | Johnson & Johnson | 60 | |
| NCT00002075Meningitis, Cryptococcal · United States | – | Completed | Pfizer | ||
| NCT00002074Meningitis, Cryptococcal · United States, Canada | – | Completed | Pfizer | ||
| NCT00002068Meningitis, Cryptococcal · United States, Canada | – | Completed | Pfizer | ||
| NCT00002041Candidiasis · United States | – | Completed | Bristol-Myers Squibb | ||
| NCT00002019Meningitis, Cryptococcal · United States | – | Completed | Liposome | ||
| NCT00001017Meningitis, Cryptococcal · United States | 3 | Completed | Pfizer | Jul 1991 | 330 |
How it is read
Names in the registry
- “Amphotericin B”, 11 entries
- “Amphotericin B Liposome for Injection (strength: 50 mg, Sichuan Huiyu Pharmaceutical Co., Ltd.)”, 1 entry
- “Amphotericin B Liposome for Injection (trade name: Ambisome®, strength: 50 mg, MAH: Gilead Sciences)”, 1 entry
- “Amphotericin B Liposome”, 1 entry
- “Comparator: amphotericin B”, 1 entry
Conditions, from the studies’ own filings
- Meningitis, Cryptococcal, 7 studies
- Invasive Fungal Infections, 1 study
- Leishmaniasis, Visceral, 1 study
- Aspergillosis, 1 study
- Candidiasis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.